01 June 2006
A comparison of automated auditory brainstem responses and transiently evoked otoacoustic emissions for universal newborn hearing screening.
Stavros G. Korres, Dimitrios G. Balatsouras, Chrysa Lyra, Dimitrios Kandiloros, Eleftherios FerekidisMed Sci Monit 2006; 12(6): CR260-263 :: ID: 451252
Abstract
Background: The aim of this study was to compare the performance of automatedauditory brainstem responses (a-ABR) and automated transiently evoked otoacoustic emissions (a-TEOAEs).Material/Methods: A prospective, case-control study in a group of newborns was performed in a maternityhospital carrying out universal newborn hearing screening. Two groups of full-term newborns were examined.The first group included 50 newborns (100 ears) who underwent: 1) a-TEOAEs, 2) a-ABR, and 3) transientlyevoked otoacoustic emissions (TEOAEs). The second group consisted of the same number of newborns whounderwent identical testing, but in a different order: 1) a-ABR, 2) a-TEOAEs, and 3) TEOAEs. All a-TEOAEand a-ABR testing was performed using the AccuScreen device and all standard TEOAE testing was performedusing the ILO88. The pass-fail results of each method were recorded and compared. Results: a-ABR yieldedlower referral rates than the otoacoustic emission tests, but the differences were not statisticallysignificant. Comparison between the two groups of study showed higher "pass" rates in the second group,indicating an order effect. Conclusions: Either method might be useful in universal newborn hearing screening.However, the lower referral rate obtained by a-ABR and its potential to recognize infants at risk forauditory neuropathy and central pathology should be considered.
Keywords: Evoked Potentials, Auditory, Brain Stem, Audiometry, Evoked Response - methods, Hearing Loss - diagnosis, Infant, Newborn, Neonatal Screening - methods, Otoacoustic Emissions, Spontaneous, Risk
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952